Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
about
The clinically relevant pharmacogenomic changes in acute myelogenous leukemiaA novel role of farnesylation in targeting a mitotic checkpoint protein, human Spindly, to kinetochoresTargeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cellsFarnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells.The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome.
P2860
Q27014790-7F491A94-B3AB-4D47-9245-759934F7BDD3Q30635394-C045D863-87A0-49EC-87F2-880F066BF6F9Q34421932-2A63C9DF-4B4A-482D-BA99-03F1388F194AQ36398735-7025AE27-26E5-4F81-9F2C-2B3DCB764909Q36526919-74119095-2AF9-48A5-A98E-91CD4271387DQ38058956-C91AC1FF-45FB-4427-A076-6529FFE49838Q38097334-B07B44B2-7C9D-4447-B2FD-11639AD9DB16Q38445385-64348E1A-9BC0-4C05-894B-24CFE500DCB6Q40892197-F32619A5-03D8-4C4A-A768-74E600E8F726Q42453294-5185716C-C20B-49E5-B470-37571760A7B5Q43089875-3DA8A999-A7E3-4ADE-B8AD-B0E26481848DQ45249684-DA8650EF-ED3E-4D9E-8E37-7AE7CC434527
P2860
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@ast
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@en
type
label
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@ast
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@en
prefLabel
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@ast
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@en
P2093
P2860
P1433
P1476
Multi-institutional phase 2 cl ...... sed acute myelogenous leukemia
@en
P2093
B Douglas Smith
Carlo Derecho
Christopher D Gocke
Elizabeth Garret-Mayer
Ellen K Ritchie
Eric J Feldman
Gail R Roboz
Hetty E Carraway
Jacqueline M Greer
John J Wright
P2860
P356
10.1182/BLOOD-2011-08-370825
P407
P577
2011-10-14T00:00:00Z